Affiliation:
1. 1Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.
2. 2Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
Abstract
Abstract
Hematopoietic stem cells (HSC) and T cells are intimately related, lineage-dependent cell populations that are extensively used as therapeutic products for the treatment of hematologic malignancies and certain types of solid tumors. These cellular therapies can be life-saving treatments; however, their efficacies are often limited by factors influencing their activity and cellular properties. Among these factors is mitochondrial metabolism, which influences the function and fate commitment of both HSCs and T cells. Mitochondria, besides being the “cellular powerhouse,” provide metabolic intermediates that are used as substrates for epigenetic modifications and chromatin remodeling, thus, driving cell fate decisions during differentiation. Moreover, mitochondrial fitness and mitochondrial quality control mechanisms are closely related to cellular function, and impairment of these mitochondrial properties associates with cellular dysfunction due to factors such as T-cell exhaustion and aging. Here, we give an overview of the role of mitochondria in shaping the behavior of these lineage-related cell populations. Moreover, we discuss the potential of novel mitochondria-targeting strategies for enhancing HSC- and T cell–based cancer immunotherapies and highlight how design and application of such approaches requires consideration of the metabolic similarities and differences between HSCs and T cells.
See related article on p. 1302.
Funder
HORIZON EUROPE European Research Council
Cancer Research Institute
Melanoma Research Alliance
Swiss Cancer Research Foundation
National Natural Science Foundation of China
Publisher
American Association for Cancer Research (AACR)
Subject
Cancer Research,Immunology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献